XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

Clinical trial NCT06091423 · RECRUITING

Trial details

NCT number

NCT06091423

Sponsor

Xiaofeng Chen

Status

RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2023-10-25

Primary completion

2025-11-25

Enrollment

43

View on ClinicalTrials.gov